Second-quarter fiscal 2009 results announced by Rosetta Genomics

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 9 2009

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009. Highlights of the second quarter of 2009 and subsequent weeks include:

  • Entering into exclusive distribution agreements with Warnex Laboratories, Super Religare Laboratories and AXA Diagnostics for our first three cancer diagnostic tests, miRview™ mets, miRview™ squamous and miRview™ meso
  • Receiving clearance from the states of California, Maryland and Rhode Island for our CLIA-certified laboratory, bringing the total to 48 U.S. states
  • Continuing development of our colon cancer screening test

  • Selling Parkway Clinical Laboratories for up to $2.5 million

  • Announcing plans for Amir Avniel to step down as chief executive officer of Rosetta Genomics once a successor is in place in order to lead Rosetta Green, the company’s early stage, cleantech division

Source:

http://www.rosettagenomics.com 

Posted in:

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study pinpoints 95 locations in the genome associated with risk of developing PTSD
New genetic variants could raise a woman's risk of cervical cancer from HPV infections
Baylor study reveals role of newly inherited DNA variants in recessive diseases
Tumor microbiomes offer new insights for enhancing cancer therapies
New interdisciplinary center aims to spark developments in synthetic genomics
Arabica coffee's genetic legacy unveiled
Achieving and maintaining ISO 27001 and BS 10012 certifications
Nanopore sequencing unveils novel telomere length patterns

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Researchers elucidate how gene mutation mechanism causes autism